Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

PTC Therapeutics earns $20M milestone from Roche on advancement of SMA candidate RG7916; shares up 1%

Published 10/12/2017, 09:33 AM
© Reuters.  PTC Therapeutics earns $20M milestone from Roche on advancement of SMA candidate RG7916; shares up 1%
PTCT
-
RHHBY
-
  • PTC Therapeutics (PTCT +0.6%) nabs a $20M milestone payment from licensee Roche (OTCQX:RHHBY) triggered by the initiation of the second (pivotal) part of a Phase 2 clinical trial, SUNFISH, assessing Orphan Drug-tagged RG7916 in pediatric and adult patients with Type 2/3 spinal muscular atrophy (SMA).
  • The confirmatory segment of the study will randomize ~168 subjects over a 24-month treatment period. According to ClinicalTrials.gov, the estimated primary completion date is April 2019.
  • RG7916 is an orally administered survival motor neuron 2 (SMN2) splicing modifier. It works by targeting the underlying molecular deficiency of SMA by modulating SMN2 splicing to increase expression of full-length SMN2 mRNA from the SMN2 gene.


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.